Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


Daily Top 10 COVID-19 publications

Deutsch | English | Español | Français | Italiano | Português; | Tiếng Việt | Türkçe


  Hepatitis

  Free Subscription


Articles published in AIDS

Retrieve available abstracts of 69 articles:
HTML format



Single Articles


    May 2020
  1. COSTINIUK CT, Jenabian MA
    Reply to: Benefits of cannabis use for metabolic disorders and survival in people living with HIV with or without hepatitis C.
    AIDS. 2020;34:955-956.
    PubMed    


  2. SANTOS ME, Protopopescu C, Zucman D, Marcellin F, et al
    Benefits of cannabis use for metabolic disorders and survival in people living with HIV with or without hepatitis C co-infection.
    AIDS. 2020;34:953-954.
    PubMed    


    March 2020
  3. RIAL-CRESTELO D, Sepulveda MA, Gonzalez-Gasca FJ, Geijo-Martinez P, et al
    Does fibrosis really regress in HIV/hepatitis C virus co-infected patients after treatment with direct antiviral agents?
    AIDS. 2020;34:427-432.
    PubMed     Abstract available


    February 2020
  4. CACHAY E
    Do we need to address stigma and mistrust to facilitate hepatitis C elimination among people living with HIV?
    AIDS. 2020;34:325-331.
    PubMed    


    January 2020
  5. GRAS J, Mahjoub N, Charreau I, Cotte L, et al
    Early diagnosis and risk factors of acute hepatitis C in high-risk MSM on preexposure prophylaxis.
    AIDS. 2020;34:47-52.
    PubMed     Abstract available


    December 2019
  6. BESSON C, Noel N, Lancar R, Prevot S, et al
    HCV or HBV coinfection and lymphoma risk in people living with HIV.
    AIDS. 2019 Dec 10. doi: 10.1097/QAD.0000000000002461.
    PubMed     Abstract available


    November 2019
  7. RIAL-CRESTELO D, Sepulveda MA, Gonzalez-Gasca FJ, Geijo-Martinez P, et al
    Does fibrosis really regress in HIV/HCV co-infected patients after treatment with direct-antiviral agents?
    AIDS. 2019 Nov 14. doi: 10.1097/QAD.0000000000002433.
    PubMed     Abstract available


  8. MARTINEZ-REBOLLAR M, Pascual PP, de la Mora L, Londono MC, et al
    Contributing awareness of autoimmune hepatitis in HIV patients.
    AIDS. 2019;33:2103-2105.
    PubMed    


    September 2019
  9. GRAS J, Mahjoub N, Charreau I, Cotte L, et al
    Early diagnosis and risk factors of acute hepatitis c in high-risk men who have sex with men on pre-exposure prophylaxis.
    AIDS. 2019 Sep 2. doi: 10.1097/QAD.0000000000002364.
    PubMed     Abstract available


    August 2019
  10. CAPPELLETTI A, Peri AM, Bisi L, Sabbatini F, et al
    Recurrent posterior reversible encephalopathy syndrome in an HIV-HCV coinfected liver transplant recipient.
    AIDS. 2019;33:1679-1681.
    PubMed    


    July 2019
  11. CEDARBAUM E, Ma Y, Scherzer R, Price JC, et al
    Contributions of HIV, HCV, and traditional vascular risk factors to peripheral artery disease in women.
    AIDS. 2019 Jul 22. doi: 10.1097/QAD.0000000000002319.
    PubMed     Abstract available


  12. MBAE M, Owen L, Elisha KK, Ndhere A, et al
    Excess early mortality in HIV/hepatitis B virus co-infected patients initiating antiretroviral therapy in Kenya.
    AIDS. 2019;33:1404-1406.
    PubMed    


    May 2019
  13. KRONFLI N, Bhatnagar SR, Hull MW, Moodie EEM, et al
    Trends in cause-specific mortality in HIV-hepatitis C coinfection following hepatitis C treatment scale-up.
    AIDS. 2019;33:1013-1022.
    PubMed     Abstract available


    March 2019
  14. BERENGUER J, Gil-Martin A, Jarrin I, Montes ML, et al
    Reinfection by hepatitis C virus following effective all-oral direct-acting antiviral drug therapy in HIV/hepatitis C virus coinfected individuals.
    AIDS. 2019;33:685-689.
    PubMed     Abstract available


  15. CORMA-GOMEZ A, Morano Amado L, Tellez F, Rivero-Juarez A, et al
    HIV infection does not impact on the risk of liver complications in HCV-infected patient with advanced fibrosis, after sustained virological response with DAA.
    AIDS. 2019 Mar 5. doi: 10.1097/QAD.0000000000002186.
    PubMed     Abstract available


  16. CHRISTIAN B, Fabian E, Macha I, Mpangala S, et al
    Hepatitis B virus coinfection is associated with high early mortality in HIV-infected Tanzanians on antiretroviral therapy.
    AIDS. 2019;33:465-473.
    PubMed     Abstract available


  17. MACHIELS JD, Braam EE, van Bentum P, van Vugt M, et al
    Vaccination with Fendrix of prior nonresponding patients with HIV has a high success rate.
    AIDS. 2019;33:503-507.
    PubMed     Abstract available


    January 2019
  18. NEWSUM AM, Kooij KW, Boyd A, Smit C, et al
    Progression of liver fibrosis following acute hepatitis C virus infection in HIV-positive MSM.
    AIDS. 2019 Jan 14. doi: 10.1097/QAD.0000000000002138.
    PubMed     Abstract available


  19. KRONFLI N, Bhatnagar SR, Hull MW, Moodie EEM, et al
    Trends in cause-specific mortality in HIV-Hepatitis C co-infection following hepatitis C treatment scale-up.
    AIDS. 2019 Jan 12. doi: 10.1097/QAD.0000000000002156.
    PubMed     Abstract available


    December 2018
  20. BERENGUER J, Gil-Martin A, Jarrin I, Montes ML, et al
    Reinfection by HCV following effective all-oral DAA therapy in HIV/HCV-coinfected individuals.
    AIDS. 2018 Dec 21. doi: 10.1097/QAD.0000000000002103.
    PubMed     Abstract available


    November 2018
  21. LOAREC A, Carnimeo V, Molfino L, Kizito W, et al
    Extremely Low Hepatitis C prevalence among HIV co-infected individuals in 4 countries in sub-Saharan Africa.
    AIDS. 2018 Nov 16. doi: 10.1097/QAD.0000000000002070.
    PubMed     Abstract available


    October 2018
  22. MOLINA-LEYVA A, Badiola J
    Severe refractory hidradenitis suppurativa successfully treated with adalimumab in an HIV-positive/hepatitis C virus-positive patient.
    AIDS. 2018;32:2436-2438.
    PubMed    


  23. ALDERSLEY J, Lorenz DR, Misra V, Uno H, et al
    Increased risk of anal squamous cell carcinoma in HIV-positive men with prior HBV infection.
    AIDS. 2018 Oct 16. doi: 10.1097/QAD.0000000000002059.
    PubMed     Abstract available


  24. VAN SANTEN DK, van der Helm JJ, Touloumi G, Pantazis N, et al
    Effect of incident hepatitis C infection on CD4 count and HIV RNA trajectories based on a multinational HIV seroconversion cohort.
    AIDS. 2018 Oct 15. doi: 10.1097/QAD.0000000000002040.
    PubMed     Abstract available


    August 2018
  25. LLEDO GM, Carrasco I, Benitez-Gutierrez LM, Arias A, et al
    Regression of liver fibrosis after curing chronic hepatitis C with oral antivirals in patients with and without HIV coinfection.
    AIDS. 2018 Aug 8. doi: 10.1097/QAD.0000000000001966.
    PubMed     Abstract available


  26. PRICE JC, Seaberg EC, Stosor V, Witt MD, et al
    AST-to-platelet ratio index increases significantly 3 years prior to liver-related death in HIV-hepatitis-coinfected men.
    AIDS. 2018 Aug 8. doi: 10.1097/QAD.0000000000001977.
    PubMed     Abstract available


    July 2018
  27. ROSSOTTI R, Maggioni M, Merli M, Orcese C, et al
    Severe cholestatic hepatitis related to abacavir/lamivudine/dolutegravir antiretroviral treatment in a HIV-1 infected subject.
    AIDS. 2018;32:1727-1729.
    PubMed    


  28. LACOMBE K
    Risk of hepatocellular carcinoma after DAA treatment in cirrhotic HIV-HCV-coinfected patients: where do we stand?
    AIDS. 2018;32:1533-1534.
    PubMed    


    June 2018
  29. LOUREIRO RV, Costa MN, Germano I, Calinas F, et al
    Pseudoresistance of hepatitis B virus to tenofovir with emtricitabine.
    AIDS. 2018;32:1387-1388.
    PubMed    


  30. PETERS L, Laut K, Resnati C, Del Campo S, et al
    Uptake of HCV treatment in HIV/HCV coinfected patients across europe in the era of direct-acting antivirals.
    AIDS. 2018 Jun 14. doi: 10.1097/QAD.0000000000001928.
    PubMed     Abstract available


  31. TARAMASSO L, Montanari L, Di Biagio A
    Hepatitis C virus direct acting antivirals impact on renal function in the first 4 weeks of treatment.
    AIDS. 2018;32:1202-1203.
    PubMed    


    April 2018
  32. ALMEIDA-BRASIL CC, Moodie EEM, Mclinden T, Hamelin AM, et al
    Medication non-adherence, multi-tablet regimens, and food insecurity are key experiences in the pathway to incomplete HIV suppression.
    AIDS. 2018 Apr 19. doi: 10.1097/QAD.0000000000001822.
    PubMed     Abstract available


    March 2018
  33. MERCHANTE N, Rodriguez-Arrondo F, Revollo B, Merino E, et al
    Hepatocellular carcinoma after sustained virological response with interferon-free regimens in HIV/HCV-coinfected patients.
    AIDS. 2018 Mar 28. doi: 10.1097/QAD.0000000000001809.
    PubMed     Abstract available


  34. LARMARANGE J, Becquet V, Masumbuko JM, Nouaman M, et al
    Implementing preexposure prophylaxis among key populations: an opportunity for patient-centered services and management of hepatitis B.
    AIDS. 2018;32:829-830.
    PubMed    


  35. VALENCIA J, Ryan P, Alvaro-Meca A, Troya J, et al
    High HIV seroconversion rate in HCV-infected drug users followed in a Harm Reduction Unit: A lost opportunity for Pre- exposure Prophylaxis.
    AIDS. 2018 Mar 20. doi: 10.1097/QAD.0000000000001806.
    PubMed     Abstract available


  36. ISMAIL MF, Wong DK, Bogoch II
    The role for hepatitis A vaccination in HIV pre-exposure prophylaxis.
    AIDS. 2018;32:675-676.
    PubMed    


    February 2018
  37. FARFOUR E, Lesprit P, Wai ACH, Mazaux L, et al
    Acute hepatitis A breakthrough in MSM in Paris area: implementation of targeted hepatitis A virus vaccine in a context of vaccine shortage.
    AIDS. 2018;32:531-532.
    PubMed    


  38. MEDRANO LM, Garcia-Broncano P, Berenguer J, Gonzalez-Garcia J, et al
    Elevated liver stiffness is linked to increased biomarkers of inflammation and immune activation in HIV/HCV-coinfected patients.
    AIDS. 2018 Feb 12. doi: 10.1097/QAD.0000000000001787.
    PubMed     Abstract available


  39. PRADAT P, Huleux T, Raffi F, Delobel P, et al
    Incidence of new hepatitis C virus infection is still increasing in French MSM living with HIV.
    AIDS. 2018 Feb 12. doi: 10.1097/QAD.0000000000001789.
    PubMed     Abstract available


    January 2018
  40. MINGUEZ C, Garcia-Deltoro M, Flores J, Galindo MJ, et al
    Interferon-free therapy for treating hepatitis C virus in difficult-to-treat HIV-coinfected patients.
    AIDS. 2018;32:337-346.
    PubMed     Abstract available


  41. ROSSI C, Saeed S, Cox J, Vachon ML, et al
    Hepatitis C virus cure does not impact kidney function decline in HIV co-infected patients.
    AIDS. 2018 Jan 23. doi: 10.1097/QAD.0000000000001750.
    PubMed     Abstract available


  42. WILLIS SJ, Cole SR, Westreich D, Edmonds A, et al
    Chronic hepatitis C virus infection and subsequent HIV viral load among women with HIV initiating antiretroviral therapy.
    AIDS. 2018 Jan 13. doi: 10.1097/QAD.0000000000001745.
    PubMed     Abstract available


  43. YOSHIMURA Y, Miyata N, Komatsu H, Tachikawa N, et al
    Remarkable plasma HIV RNA decrease by ombitasvir/paritaprevir/ritonavir in an HIV-HCV coinfection case.
    AIDS. 2018;32:128-129.
    PubMed    


    December 2017
  44. NGUYEN VK, Greenwald ZR, Trottier H, Cadieux M, et al
    Incidence of sexually transmitted infections before and after Pre-Exposure Prophylaxis for HIV: a cohort study.
    AIDS. 2017 Dec 12. doi: 10.1097/QAD.0000000000001718.
    PubMed     Abstract available


    November 2017
  45. LI F, Ma L, Feng Y, Ruan Y, et al
    HIV-1 and Hepatitis C virus selection bottleneck in Chinese people who inject drugs.
    AIDS. 2017 Nov 30. doi: 10.1097/QAD.0000000000001702.
    PubMed     Abstract available


  46. KUNIHOLM MH, Liang H, Anastos K, Gustafson D, et al
    Association of a 3' untranslated region polymorphism in proprotein convertase subtilisin/kexin type 9 with HIV viral load and CD4+ levels in HIV/hepatitis C virus coinfected women.
    AIDS. 2017;31:2483-2492.
    PubMed     Abstract available


  47. MINGUEZ C, Garcia-Deltoro M, Flores J, Galindo MJ, et al
    Interferon-free therapy for treating HCV in difficult-to-treat HIV-coinfected patients as implemented in routine medical practice.
    AIDS. 2017 Nov 10. doi: 10.1097/QAD.0000000000001699.
    PubMed     Abstract available


    October 2017
  48. TARTAGLIA A, Ferrara SM, Sica S, Santantonio T, et al
    Successful treatment with tenofovir alafenamide of a HIV/hepatitis B virus coinfected patient with HIV and hepatitis B virus drug resistance, end-stage renal disease on haemodialysis.
    AIDS. 2017;31:2314-2315.
    PubMed    


    September 2017
  49. ZOBOLI F, Ripamonti D, Benatti SV, Comi L, et al
    Autoimmune hepatitis and HIV infection: two case reports and review of the literature.
    AIDS. 2017;31:2172-2175.
    PubMed    


  50. LAKE AC
    Hepatitis B reactivation in a long-term nonprogressor due to nivolumab therapy.
    AIDS. 2017;31:2115-2118.
    PubMed     Abstract available


  51. THORNTON AC, Jose S, Bhagani S, Chadwick D, et al
    Hepatitis B, hepatitis C and mortality among HIV-positive individuals.
    AIDS. 2017 Sep 18. doi: 10.1097/QAD.0000000000001646.
    PubMed     Abstract available


  52. KUNIHOLM MH, Liang H, Anastos K, Gustafson D, et al
    Association of a 3' Untranslated Region Polymorphism in PCSK9 with HIV Viral Load and CD4+ Levels in HIV/Hepatitis C Virus Co-Infected Women.
    AIDS. 2017 Sep 18. doi: 10.1097/QAD.0000000000001648.
    PubMed     Abstract available


    July 2017
  53. SARIS J, van den Berk G, Moha DA, van der Meer J, et al
    Successful implementation of hepatitis C virus treatment in two large HIV clinics in Amsterdam: hepatitis C virus treatment cascade of care.
    AIDS. 2017;31:1779-1780.
    PubMed    


  54. LEBRUN D, Hentzien M, Cuzin L, Rey D, et al
    Epidemiology of autoimmune and inflammatory diseases in a French Nationwide HIV cohort.
    AIDS. 2017 Jul 18. doi: 10.1097/QAD.0000000000001603.
    PubMed     Abstract available


  55. HOORNENBORG E, Achterbergh RCA, Schim van der Loeff MF, Davidovich U, et al
    MSM starting preexposure prophylaxis are at risk of hepatitis C virus infection.
    AIDS. 2017;31:1603-1610.
    PubMed     Abstract available


  56. ZENG H, Wang L, Liu P, Liao L, et al
    Seroprevalence of hepatitis E virus in HIV-infected patients in China.
    AIDS. 2017 Jul 7. doi: 10.1097/QAD.0000000000001585.
    PubMed     Abstract available


  57. SINGH KP, Crane M, Audsley J, Lewin SR, et al
    HIV-hepatitis B virus co-infection: epidemiology, pathogenesis, and treatment.
    AIDS. 2017 Jul 7. doi: 10.1097/QAD.0000000000001574.
    PubMed     Abstract available


  58. VANHOMMERIG JW, Bezemer D, Molenkamp R, Van Sighem AI, et al
    Limited overlap between phylogenetic HIV and HCV clusters illustrates the dynamic sexual network structure of Dutch HIV-infected MSM.
    AIDS. 2017 Jul 7. doi: 10.1097/QAD.0000000000001592.
    PubMed     Abstract available


    June 2017
  59. TODESCO E, Demeret S, Calin R, Roque-Afonso AM, et al
    Chronic hepatitis E in HIV/HBV coinfected patient: lack of power of sofosbuvir-ribavirin.
    AIDS. 2017;31:1346-1348.
    PubMed    


  60. GRIESBECK M, Valantin MA, Lacombe K, Samri-Hassimi A, et al
    Hepatitis C virus drives increased type I interferon-associated impairments associated with fibrosis severity in antiretroviral treatment-treated HIV-1-hepatitis C virus-coinfected individuals.
    AIDS. 2017;31:1223-1234.
    PubMed     Abstract available


    May 2017
  61. MEIJIDE H, Pertega S, Rodriguez-Osorio I, Castro-Iglesias A, et al
    Increased incidence of cancer observed in HIV/hepatitis C virus-coinfected patients versus HIV-monoinfected.
    AIDS. 2017;31:1099-1107.
    PubMed     Abstract available


  62. HOORNENBORG E, Achterbergh RCA, Schim Van Der Loeff MF, Davidovich U, et al
    Men who have sex with men starting pre-exposure prophylaxis (PrEP) are at risk of HCV infection: evidence from the Amsterdam PrEP study.
    AIDS. 2017 May 1. doi: 10.1097/QAD.0000000000001522.
    PubMed     Abstract available


    March 2017
  63. MONTES ML, Olveira A, Ahumada A, Aldamiz T, et al
    Similar effectiveness of direct-acting antiviral against hepatitis C virus in patients with and without HIV infection.
    AIDS. 2017 Mar 29. doi: 10.1097/QAD.0000000000001465.
    PubMed     Abstract available


  64. MEIJIDE H, Pertega S, Rodriguez-Osorio I, Castro-Iglesias A, et al
    Increased incidence of cancer observed in HIV/HCV-coinfected patients versus HIV-monoinfected, 1993-2014.
    AIDS. 2017 Mar 21. doi: 10.1097/QAD.0000000000001448.
    PubMed     Abstract available


  65. PRICE H, Dunn D, Zachary T, Vudriko T, et al
    Hepatitis B serological markers and plasma DNA concentrations: baseline results from the DART trial.
    AIDS. 2017 Mar 21. doi: 10.1097/QAD.0000000000001454.
    PubMed     Abstract available


  66. GRIESBECK M, Valantin MA, Lacombe K, Samri-Hassimi A, et al
    HCV drives increased type I IFN-associated impairments associated to fibrosis severity in ART-treated HIV-1-HCV coinfected individuals.
    AIDS. 2017 Mar 21. doi: 10.1097/QAD.0000000000001455.
    PubMed     Abstract available


    January 2017
  67. STREECK H, Verheyen J, Storim J, Dittmer U, et al
    Pre-exposure prophylaxis failure with tenofovir disoproxil.
    AIDS. 2017;31:176-177.
    PubMed    


    November 2016
  68. YOUNAS M, Carrat F, Finge S, Desaint C, et al
    Immune activation, smoking, and vaccine response.
    AIDS. 2016.
    PubMed     Abstract available


    March 2016
  69. AUDSLEY J, Bent SJ, Littlejohn M, Avihingsanon A, et al
    Effects of long-term tenofovir-based cART in HIV-HBV co-infection on persistent HBV viremia and the role of HBV quasispecies diversity.
    AIDS. 2016.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Hepatitis is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: